Horizontal Tabs


Fibromyalgia is a chronic disease characterized by bone and muscle pain, multisensorial hypersensitivity, sleep disorders and tiredness. Since cannabinoids show analgesic and anti-inflammatory properties, they show potential to be used to treat fibromyalgia symptoms.


Wiki Entry

Horizontal Tabs

Top Right

Prescription Advice

Preclinical evidence suggests THC may be beneficial in the treatment of fibromyalgia.

Given the nature of the disease, sublingual application may be beneficial.

Please follow generic prescription advice.

Please note that, while based on preclinical and/or clinical research, this prescription advice is solely intended as a guideline to help physicians determine the right prescription. We intend to continuously update our prescription advice based on patient and/or expert feedback. If you have information that this prescription advice is inaccurate, incomplete or outdated please contact us here.

Similar Entries

Horizontal Tabs

Literature Discussion

Fibromyalgia has been considered as a clinical endocannabinoid deficiency (CECD). This would mean that fibromyalgia  would be a disease related to the endocannabinoid system and it could be treated with cannabinoids (Russo, 2004, 2008, 2016).

A recent review of the effects of cannabinoids in fibromyalgia concluded that synthetic cannabinoid based drug Nabilone can be effective to treat symptoms of fibromialgya (Walitt, Klose, Fitzcharles, Phillips, & Häuser, 2016).

In another review, Lynch and Campbell (2011) also concluded that cannabinoids can be useful to treat fibromyalgia-related pain.

However, other review concluded that there is not enough evidence to say that cannabinoids can help to treat any fibromyalgia related symptom (Fitzcharles, Baerwald, Ablin, & Häuser, 2016).

Fiz, Durán, Capellà, Carbonell and Farré (2011) compared the subjective perception of the fibromyalgia symptoms between 28 cannabis users and 28 non-cannabis users. Results showed a reduction of pain and stiffness and increased relaxation, somnolence and feeling of well being. However, there were no differences in other variables related to quality of life.

Patients using herbal cannabis to treat fibromyalgia showed also negative psychosocial parameters which were not present in other patients using prescription cannabinoids (Ste-Marie, Fitzcharles, Gamsa, Ware, & Shir, 2012).

A sub-population of patients with fibromyalgia showed lower pain perception after daily administration of THC (2.5 to 15mg). Authors suggested these effects are due to the analgesic action of THC in the central nervous system (Schley et al., 2006)

The use of the synthetic cannabinoid-based drug Nabilone showed improvement in pain reduction and life quality in patients with fibromyalgia (Skrabek, Galimova, Ethans, & Perry, 2008).


Fitzcharles, M.-A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz (Berlin, Germany), 30(1), 47-61.

Fiz, J., Durán, M., Capellà, D., Carbonell, J., & Farré, M. (2011). Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PloS One, 6(4), e18440.

Lynch, M. E., & Campbell, F. (2011). cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72(5), 735-744.

Russo, E. B. (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in Migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinology Letters, 25(1-2), 31-39.

Russo, E. B. (2008). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in Migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinology Letters, 29(2), 192-200.

Russo, E. B. (2016). Clinical endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and cannabinoid Research, 1(1), 154-165.

Schley, M., Legler, A., Skopp, G., Schmelz, M., Konrad, C., & Rukwied, R. (2006). Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Current Medical Research and Opinion, 22(7), 1269-1276.

Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008). Nabilone for the treatment of pain in fibromyalgia. The Journal of pain: Official Journal of the American pain Society, 9(2), 164-173.

Ste-Marie, P. A., Fitzcharles, M.-A., Gamsa, A., Ware, M. A., & Shir, Y. (2012). Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. arthritis Care & Research, 64(8), 1202-1208.

Walitt, B., Klose, P., Fitzcharles, M.-A., Phillips, T., & Häuser, W. (2016). cannabinoids for fibromyalgia. The Cochrane Database of Systematic Reviews, 7, CD011694.